Lundbeck announced a voluntary nationwide recall of two lots of NeoProfen (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. The two lots being recalled are Lot# 1734991 (expiration date: 4/11) and Lot# 1922319 (expiration date: 3/12). These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage.
NeoProfen is a non-steroidal anti-inflammatory drug (NSAID) indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500–1500g, who are no more than 32 weeks gestational age when usual medical management (eg, fluid restriction, diuretics, respiratory support, etc.) is ineffective.
For more information call (866) 402-8520 or visit www.lundbeck.com.